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 Anorexia, de( ned as the loss of the desire 
to eat, is common in patients with end-
stage renal disease (ESRD) receiving 
chronic dialysis. Anorexia reduces oral 
energy and protein intakes, thus contrib-
uting to the development of cachexia, 
which is prevalent in ESRD. Anorexia 
and cachexia are associated with 
increased hospitalization rates, poor 
quality of life, and an increased risk of 
morbidity and mortality in ESRD 
patients. - ere is an urgent need for the 
development of new therapeutic agents 
for this potentially fatal complication of 
ESRD. 1 – 3 
 - e mechanism of cachexia in ESRD 
patients is complex and has not been 
fully identi( ed. 1,2 Clinical and experi-
mental therapeutic strategies include 
appetite stimulants (for example, meges-
trol acetate), intradialytic parenteral 
nutrition, high-intensity progressive 
resistance training, ubiquitin – proteas-
ome inhibitors (for example, borte-
zomib), and correction of metabolic 
acidosis in ESRD patients. 3 Recently, 
ghrelin and its analogues have emerged 
as potential therapeutic agents for ano-
rexia and cachexia in ESRD. 
 Ghrelin, first described by Kojima 
 et al. , 4 is a peptide of 28 amino acids that 
stimulates growth hormone (GH) 
release from the pituitary. Ghrelin, a 
natural ligand of the growth hormone 
secretagogue receptor (GHS-R) type 1a, 
is secreted into the bloodstream prima-
rily from the stomach and degraded by 
the kidney. Apart from the stomach, 
lower amounts of ghrelin have been 
detected in many other tissues. Ghrelin 
stimulates GH-releasing activity in both 
animals and humans. Ghrelin is more 
potent than GH-releasing hormone 
and stimulates GH release in a dose-
 dependent manner. The two major 
molecular forms of circulating ghrelin 
are acyl ghrelin (  <  10 % ), which pro-
motes food intake, and des-acyl ghrelin, 
which induces a negative energy bal-
ance. Plasma ghrelin concentrations in 
chronic kidney diseases have been 
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 Anorexia and cachexia are prevalent in patients with end-stage renal 
disease (ESRD) and are associated with increased risks of morbidity and 
mortality. Ashby  et al. provide evidence that subcutaneous 
administration of synthetic ghrelin stimulated food intake in ESRD 
patients over a week, with no subsequent reduction in energy intake 
and no significant adverse effects. However, the clinical utility of ghrelin 
will depend on long-term outcomes in improving appetite and lean 
body mass as well as morbidity and mortality. 
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reported to be increased, normal, or 
decreased depending on the molecular 
forms measured. Recent studies have 
suggested that elevated levels of des-acyl 
ghrelin could be involved in the  anorexia 
in ESRD patients. 5 
 - e salutary e: ects of ghrelin on food 
intake and meal appreciation suggest that 
it could be an effective treatment for 
 anorexic ESRD patients. Wynne and 
 colleagues reported that a single subcu-
taneous injection of ghrelin (3.6  nmol /
 kg) enhances short-term (3-day) food 
intake in dialysis patients. 6 Subcutaneous 
ghrelin administration resulted in a two-
fold increase in short-term energy intake 
in a cohort of nine anorexic peritoneal 
dialysis patients. Although these results 
are encouraging, it is possible that the 
initial short-term increase in food intake 
may be followed by subsequent decline, 
negating any long-term bene( cial e: ect 
of ghrelin administration. Ashby  et al. 
(this issue), 7 from the same research 
group, evaluated the nutritional and car-
diovascular e: ect of daily subcutaneous 
ghrelin injection (12   g / kg) over a period 
of 7 days in 12 anorexic ESRD patients. 
- eir results suggest that subcutaneous 
administration of synthetic ghrelin 
 stimulates food intake among dialysis 
patients over the intermediate term. 
Energy expenditure, measured with free-
living pulse and motion monitors, is 
unchanged. Importantly, there was no 
subsequent compensatory reduction in 
energy intake in these patients; this sug-
gests potential long-term beneficial 
effects. No significant adverse effects 
were observed during the study. Pertur-
bations in systolic and diastolic blood 
pressure were resolved within 2  h of 
ghrelin administration. Total plasma 
ghrelin and acyl ghrelin levels were sig-
ni( cantly elevated (eightfold and 80-fold, 
respectively, over baseline) at 30  min 
aP er the subcutaneous ghrelin injection. 
- ese new ( ndings bolster the potential 
therapeutic application of ghrelin and its 
analogues as an appetite-stimulating and 
anabolic  strategy in ESRD. 
 GHRELIN AND THE PHYSIOLOGY OF 
WEIGHT REGULATION 
 Food intake is regulated by  interaction 
between peripheral hormonal  signals 
see original article on page 199
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from those of wild-type littermates. 10 
Both acyl ghrelin knockout and GHS-
R knockout mice are resistant to high-
fat diet – induced obesity, suggesting 
that there are indispensable roles for 
endogenous acyl ghrelin and GHS-R 
in the metabolic adaptation to nu-
tritional availability. Simultaneous 
deletion of ghrelin and its receptor 
increases motor activity and energy 
expenditure, implying the existence 
of additional as-yet unknown molec-
ular components of the endogenous 
ghrelin system. Moreover, there is 
evidence that weight gain in ghrelin-
treated rats is related to the gain of fat 
mass, as determined by nuclear mag-
netic resonance imaging, without any 
change in lean body mass. 11 These re-
sults are supported by  in vitro experi-
ments in which ghrelin stimulates the 
differentiation of preadipocytes and 
antagonizes lipolysis, suggesting that 
ghrelin acts directly on adipocytes to 
stimulate adipogenesis. Studies on the 
long-term effects of ghrelin treatment 
are still lacking. In human trials, the 
effects of intermediate-term treatment 
with ghrelin suggest a dampening of 
effect on food intake, with only mod-
est increases after 3 weeks of therapy 
in chronic heart failure patients. 12 A 
level of tolerance in appetite-regulat-
ing centers and / or other factors may 
override the long-term appetite-stim-
ulating effects of ghrelin. Potential 
side effects of ghrelin therapy have 
to be considered. Ghrelin infusion 
acutely induces lipolysis and insulin 
resistance independently of GH and 
cortisol. 13 Thus, it will be important to 
follow subjects for the risk of diabetes 
while on long-term ghrelin treatment. 
Finally, a major limitation of treatment 
based on natural hormones is the need 
for parenteral administration, because 
of the large size of the molecule. The 
long-term therapeutic potential of 
GHS-R agonists will likely rest with 
orally bioavailable compounds. DeBo-
er  et al. recently showed that ghrelin 
and small-molecule GHS-R agonist 
administration, over a 2-week period, 
increased food intake and lean body 
mass retention and decreased systemic 
inflammation and muscle catabolism 
and regulatory areas of the brain. 
 Circulating hormones carry informa-
tion about energy balance to hypotha-
lamic structures that control eating 
and energy output. Both long-term 
and short-term regulators are in-
volved. Long-term regulators include 
leptin and insulin, which monitor the 
amount of body fat. Leptin decreases 
appetite, in part, by inhibiting neu-
rons that produce neuropeptide Y and 
agouti-related peptide, which are orex-
igenic peptides, while stimulating neu-
rons in the arcuate nucleus region of 
the hypothalamus to produce melano-
cortins that are anorexigenic ( Figure 1 ). 
Ghrelin is a short-term regulator. It 
stimulates appetite and food intake and 
plays a role in meal initiation. Fasting 
increases ghrelin and decreases leptin 
production, leading to the activation 
of an orexigenic pathway. - e e: ect of 
ghrelin in the hypothalamus is oppo-
site that of leptin ( Figure 1 ), through 
activation of the hypothalamic neu-
ropeptide Y 1 receptor pathway; release 
of agouti-related peptide and possibly 
orexin; inhibition of the release of   -
melanocyte-stimulating hormone and 
amphetamine-regulated transcript; and 
activation of GHS-R on vagal  a: erents 
in the stomach. 8,9 
 GHRELIN AND ITS ANALOGUES AS POTENTIAL 
THERAPEUTIC AGENTS FOR CACHEXIA 
 Recent studies support the potential 
of ghrelin and its analogues as thera-
peutic agents in a number of diseases 
associated with cachexia. Ghrelin may 
play a role in the regulation of meta-
bolic balance and improve the cachet-
ic condition through GH-dependent 
or GH-independent pathways. Atten-
tion to ghrelin ’ s role in energy regula-
tion was initiated by pharmacologi-
cal studies in which ghrelin seemed 
to stimulate GH release and appetite, 
but ghrelin ’ s physiological role in en-
ergy homeostasis has not been well 
established. Ghrelin-null mice are not 
anorexic dwarfs; their size, growth 
rate, food intake, body composition, 
reproduction, gross behavior, and tis-























 Figure 1  |  Schematic representation of the activation of distinct neuroendocrine signaling 
pathways by ghrelin and leptin. Leptin is released from adipocytes as a function of the amount 
of fat and reduces food intake by acting on two hypothalamic pathways. Leptin stimulates an 
anorexigenic pathway while inhibiting an orexigenic pathway; both of them originate in the 
arcuate nucleus of the hypothalamus and project to the paraventricular nucleus and the lateral 
hypothalamic area. Ghrelin is released from the stomach. The effect of ghrelin in the hypothalamus 
is opposite that of leptin. Ghrelin stimulates both energy gain and the secretion of growth 
hormone by acting on the anterior pituitary. Fasting decreases leptin and increases ghrelin 
production, leading to the activation of the orexigenic pathway. ARC, arcuate nucleus; GH, growth 
hormone; GHRH, growth hormone-releasing hormone; LHA, lateral hypothalamic area; PVN, 
paraventricular nucleus. (Figure adapted and modified with permission from Macmillan Publishers 
Ltd:  Nature Reviews Neuroscience ,  ‘ Ghrelin: an orexigenic and somatotrophic signal from the 
stomach, ’ © 2001. 9 ) 
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in rats with cachexia associated with 
chronic kidney disease. 14 
 In conclusion, despite reports of the 
short- and intermediate-term success of 
ghrelin administration in treating 
anorexia and cachexia in ESRD patients, 
we must await results of studies on its 
long-term eK  cacy in improving appetite, 
weight gain, and lean body mass as well as 
quality of life. 
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 - ere is substantial evidence that arterial 
under( lling, due to either decreased car-
diac output, e.g., heart failure, or systemic 
arterial vasodilation, e.g., cirrhosis, is 
associated with activation of the neurohu-
moral axis, including the sympathetic 
nervous system, the renin – angiotensin 
system, and arginine vasopressin (AVP). 
This neurohumoral response involves 
compensatory systemic vasoconstriction 
and renal sodium and water restriction in 
order to attenuate the arterial under( lling, 
that is, the so-called decreased e: ective 
arterial blood volume. What is not known 
is whether there is an interaction at the 
cellular and molecular levels between 
these responses to arterial under( lling. 
 Li  et al. 1 (this issue) provide experimen-
tal evidence indicating an importance 
of angiotensin II in normal AVP-medi-
ated urinary concentration. There are 
 several potential mechanisms whereby 
 angiotensin II could modulate water 
 homeostasis, and thus angiotensin II 
receptor knockout (KO) mice would be 
expected to have impaired urine-concen-
trating capacity. - ere is substantial evi-
dence that angiotensin II stimulates the 
thirst center in the brain, thereby leading 
to increased thirst and water intake. 2 
- us, the angiotensin II type 1a (AT 1a ) 
receptor KO mice might be expected to 
decrease their water intake unless other 
intervening e: ects occur. In this regard, 
Li  et al. 1 demonstrated that these KO mice 
actually have an increase, not a decrease, 
in water intake. Although somewhat con-
troversial, there is evidence that angio-
tensin II may stimulate AVP release. 3,4 Li 
 et al. 1 did demonstrate a decrease in basal 
plasma AVP concentrations in AT 1a 
receptor KO mice, as compared with wild-
type mice. - is, however, has not been a 
consistent ( nding in these AT 1a receptor 
KO mice. 5 In order to demonstrate partial 
central diabetes insipidus in the AT 1a KO 
mice, for which Li  et al. 1 propose a role, it 
would be necessary to perform fluid 
restriction — which maximally concen-
trates urine in wild-type mice — and then 
administer exogenous AVP . Exogenous 
AVP would not increase urinary 
 osmolality further aP er such F uid restric-
tion in wild-type mice; however, a further 
increment in urinary osmolality aP er F uid 
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 Mice deficient in the angiotensin II type 1a (AT 1a ) receptor demonstrate 
a vasopressin-resistant nephrogenic diabetes insipidus. These knockout 
mice exhibit a threefold increase in 24-h urine excretion. Neither 2 weeks 
of exogenous vasopressin nor 5 days of fluid restriction reversed this 
polyuric state. This nephrogenic diabetes insipidus was associated with 
reductions in adenylyl cyclase protein and in the phosphorylated 
mitogen-activated protein kinase extracellular signal – regulated kinase 
1 / 2 . The results support an important interaction between vasopressin 
and angiotensin II in maximal urinary concentration. 
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